Tenon Medical (TNON) 10-Q 9 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-41364
Entity Registrant Name	TENON MEDICAL, INC.
Entity Central Index Key	0001560293
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-5574718
Entity Address, Address Line One	104 Cooper Court
Entity Address, City or Town	Los Gatos
Entity Address, Country	CA
Entity Address, Postal Zip Code	95032
City Area Code	408
Local Phone Number	649-5760
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	TNON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,251,299

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 3,179	$ 2,129
Short-term investments	1,737	6,441
Accounts receivable	316	228
Inventory	416	415
Prepaid expenses	193	134
Total current assets	5,841	9,347
Fixed assets, net	852	793
Deposits	51	51
Operating lease right-of-use asset	818	873
Deferred offering costs	67	25
TOTAL ASSETS	7,629	11,089
Current liabilities:
Accounts payable	928	550
Accrued expenses	530	717
Current portion of accrued commissions	1,059	1,035
Current portion of operating lease liability	235	228
Total current liabilities	2,752	2,530
Accrued commissions, net of current portion	1,781	1,624
Operating lease liability, net of current portion	622	683
Total liabilities	5,155	4,837
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):
Common stock, $0.001 par value; 130,000,000 shares authorized at March 31, 2023 and December 31, 2022; 11,251,299 and 11,236,801 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	11	11
Additional paid-in capital	46,873	45,833
Accumulated deficit	(44,322)	(39,492)
Accumulated other comprehensive loss	(88)	(100)
Total stockholders' equity	2,474	6,252
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 7,629	$ 11,089

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock par or stated value per share	$ 0.001	$ 0.001
Common stock shares authorized	130,000,000	130,000,000
Common stock shares issued	11,251,299	11,236,801
Common stock shares outstanding	11,251,299	11,236,801

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 433	$ 71
Cost of revenue	480	275
Gross Loss	(47)	(204)
Operating Expenses
Research and development	834	562
Sales and marketing	2,026	276
General and administrative	1,979	1,037
Total Operating Expenses	4,839	1,875
Loss from Operations	(4,886)	(2,079)
Other Income (Expense)
Gain on investments	56	1
Interest expense	0	(274)
Other income (expense)	0	(1)
Total Other Income (Expense), net	56	(274)
Net Loss	$ (4,830)	$ (2,353)
Net Loss Per Share of Common Stock
Basic	$ (0.43)	$ (2.38)
Diluted	$ (0.43)	$ (2.38)
Weighted Average Shares of Common Stock Outstanding
Basic	11,242	990
Diluted	11,242	990
Statement of Comprehensive Income [Abstract]
Net loss	$ (4,830)	$ (2,353)
Unrealized gain on investments	13	0
Foreign currency translation adjustment	(1)	0
Total Comprehensive Loss	$ (4,818)	$ (2,353)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]
Beginning Balance at Dec. 31, 2021						$ 12,367	$ 1,272
Beginning Balance (in shares) at Dec. 31, 2021						2,550,763	491,222
Beginning Balance at Dec. 31, 2021	$ (20,552)	$ 1	$ 113	$ (20,575)	$ (91)
Beginning Balance (in shares) at Dec. 31, 2021		989,954
Stock-based compensation expense	169		169
Net loss	(2,353)			(2,353)
Ending Balance at Mar. 31, 2022						$ 12,367	$ 1,272
Ending Balance (in shares) at Mar. 31, 2022						2,550,763	491,222
Ending Balance at Mar. 31, 2022	(22,736)	$ 1	282	(22,928)	(91)
Ending Balance (in shares) at Mar. 31, 2022		989,954
Beginning Balance at Dec. 31, 2022						$ 0	$ 0
Beginning Balance (in shares) at Dec. 31, 2022						0	0
Beginning Balance at Dec. 31, 2022	6,252	$ 11	45,833	(39,492)	(100)
Beginning Balance (in shares) at Dec. 31, 2022		11,236,801
Stock-based compensation expense	1,040		1,040
Release of restricted stock units , shares		14,498
Other comprehensive income	12				12
Net loss	(4,830)			(4,830)
Ending Balance at Mar. 31, 2023						$ 0	$ 0
Ending Balance (in shares) at Mar. 31, 2023						0	0
Ending Balance at Mar. 31, 2023	$ 2,474	$ 11	$ 46,873	$ (44,322)	$ (88)
Ending Balance (in shares) at Mar. 31, 2023		11,251,299

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash Flows from Operating Activities
Net loss	$ (4,830)	$ (2,353)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	0	274
Stock-based compensation expense	1,040	169
Depreciation and amortization	25	10
Amortization of operating right-of-use asset	55	51
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(88)	11
Inventory	(1)	(414)
Prepaid expenses and other assets	(95)	5
Accounts payable	378	(51)
Accrued expenses	(6)	(118)
Operating lease liability	(54)	(48)
Net cash used in operating activities	(3,576)	(2,464)
Cash Flows from Investing Activities
Sales of short-term investments	4,753	4,404
Purchases of short-term investments	0	0
Purchases of property and equipment	(84)	(128)
Net cash provided by investing activities	4,669	4,276
Cash Flows from Financing Activities
Deferred offering costs	(42)	(54)
Net cash used in financing activities	(42)	(54)
Effect of foreign currency translation on cash flow	(1)	2
Net Increase in Cash and Cash Equivalents	1,050	1,760
Cash and Cash Equivalents at Beginning of Period	2,129	2,917
Cash and Cash Equivalents at End of Period	$ 3,179	$ 4,677

Organization and Business

Organization and Business	3 Months Ended
	Mar. 31, 2023
Organization And Business Disclosure [Abstract]
Organization and Business	1. Organization and Business Nature of operations Tenon Medical, Inc. (the “Company”), was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the “SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for its primary product, The Catamaran™ Principles of consolidation The condensed consolidated financial statements of the Company include the accounts of the Company and its wholly-owned subsidiary, Tenon Technology AG (“TTAG”), a Swiss company. All intercompany balances and transactions have been eliminated in consolidation. The financial statements of TTAG are prepared for the same reporting period as the parent, using consistent accounting policies in all material respects.

Summary of Significant Accounti

Summary of Significant Accounting Principles	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	2. Summary of Significant Accounting Principles Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2022 has been derived from the Company’s audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 10, 2023. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in management’s opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021 included in its Annual Report of Form 10-K filed with the SEC on March 10, 2023. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2023. Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of March 31, 2023 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these condensed consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence Income Taxes The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Net loss per share Basic net loss per share is based upon the weighted The Company had the following dilutive common stock equivalents as of March 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive: March 31, March 31, Outstanding restricted stock units 1,304,032 — Outstanding stock options 974,344 727,394 Outstanding warrants 96,000 25,000 Common shares convertible from notes payable — 2,118,591 Common shares convertible from preferred stock — 1,520,996 Total 2,374,376 4,391,981 Recent Accounting Pronouncements Adopted In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This standard requires an impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, each reporting entity estimate s on of Recent Accounting Pronouncements Not Yet Adopted There have been no accounting pronouncements or changes in accounting pronouncements in the three months ended March 31, 2023 that are significant or

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments [Abstract]
Investments	3. Investments The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of March 31, 2023 and December 31, 2022: Level 2 Corporate debt securities: March 31, 2023 $ 1,737 December 31, 2022 $ 6,441 Cost and fair value of available-for-sale investments as of March 31, 2023 and December 31, 2022 are as follows: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: March 31, 2023 $ 1,740 $ — $ (3 ) $ 1,737 December 31, 2022 $ 6,457 $ — $ (16 ) $ 6,441 All of the investments with gross unrealized losses have been in a continuous loss position for less than 12 months. During the three months ended March 31, 2023 and 2022, the Company did not recognize any significant other-than-temporary impairment losses because the Company does not intend to sell the investments before recovery of their amortized cost bases. During the three months ended March 31, 2023 and 2022, there were net gains of approximately $56 and $1, respectively, included in the Company’s net loss. Accrued interest as of March 31, 2023 and December 31, 2022 was approximately $10 and $13, respectively, and is included in prepaid expenses in the Company’s condensed consolidated balance sheet s .

Fixed Assets, Net

Fixed Assets, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Fixed Assets, Net	4. Fixed Assets , Net Fixed assets, net, consisted of the following: March 31, 2023 December 31, 2022 Construction in progress $ 530 $ 601 Catamaran t s 348 193 IT e 556 56 Lab e 14 14 Office f 9 9 Fixed assets, gross 957 873 Less: accumulated depreciation (105 ) (80 ) Fixed assets, net $ 852 $ 793 Construction in progress is made up of reusable components that will become Catamaran Tray Sets. Depreciation expense was approximately $25 and $10 for the three months ended March 31, 2023 and 2022, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following: March 31, 2023 December 31, 2022 Accrued compensation $ 321 $ 452 Other accrued expenses 209 265 Total accrued expenses $ 530 $ 717

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	6. Leases In June 2021, the Company entered into a facility lease agreement for its company headquarters in Los Gatos, California. This non- cancellable operating lease expires in June 2026. The Company includes options that are reasonably certain to be exercised as part of the determination of lease terms. The Company may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within operating leases. In addition to base rent payments, leases may require the Company to pay directly for taxes and other non-lease components, such as insurance, maintenance, and other operating expenses, which may be dependent on usage or vary month-to-month. Non-lease components were considered and determined not to be material. The Company determined if an arrangement is a lease at inception of the contract and performed the lease classification test as of the lease commencement date. R ight-of-use r ight-of-use Operating lease costs for the facility lease were $73 and $135 for the three months ended March 31, 2023 and 2022, respectively. Lease costs are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Supplemental balance sheet information related to leases was as follows: March 31, December 31, 2023 2022 Operating lease right-of-use assets $ 818 $ 873 Operating lease liability, current $ (235 ) $ (228 ) Operating lease liability, noncurrent (622 ) (683 ) Total operating lease liabilities $ (857 ) $ (911 ) Future maturities of operating lease liabilities as of March 31, 2023 were as follows: 2023 $ 221 2024 301 2025 310 2026 144 Total lease payments 976 Less: imputed interest (119 ) Present value of operating lease liabilities $ 857 Other information: Cash paid for operating leases for the three months ended March 31, 2023 $ 72 Cash paid for operating leases for the three months ended March 31, 2022 $ 70 Remaining lease term - operating leases (in years) 3.25 Average discount rate - operating leases 8.0 %

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity The Amended and Restated Certificate of Incorporation dated February 18, 2014 authorized the issuance of 3,937,550 shares of common stock and 2,099,525 shares of preferred stock, with a par value of $0.001 per share. In April 2021 the Company increased the number of authorized shares to 7,000,000 shares of common stock and 2,460,802 shares of preferred stock, and increased the number of authorized shares of Series A Preferred Stock to 1,798,905. In October 2021 the Company increased the number of authorized shares to 10,487,904 shares of common stock and 3,297,061 shares of preferred stock. In February 2022, the Company increased the number of authorized shares to 130,000,000 shares of common stock and 20,000,000 shares of preferred stock. With respect to the preferred stock, 4,500,000 shares are designated Series A Preferred Stock and 491,222 shares are designated Series B Preferred Stock. As of March 31, 2023 and December 31, 2022, there were no shares of Series A Preferred stock or Series B Preferred Stock issued and outstanding. Reverse Stock Split On April 6, 2022, the Company effected a 1:2 reverse stock split (the “Reverse Stock Split”) by filing an amendment to the Company’s Amended and Restated Certificate of Initial Public Offering On April 26, 2022, the Company’s Registration Statement relating to the IPO was declared effective by the SEC. The IPO consisted of 3,200,000 shares of common stock, par value $0.001 per share at a public offering price of $5.00 per share. Pursuant to the Underwriting Agreement dated April 26, 2022, between the Company, The Benchmark Company, LLC (“Benchmark”) and Valuable Capital Limited (together with Benchmark, the “Underwriters”), the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock at an exercise price of $5.00 per share. The warrants expire on the fifth anniversary of the commencement of sales under the IPO. On April 27, 2022, the shares of the Company’s common stock began trading on the Nasdaq Capital Market LLC under the symbol “TNON.” On April 29, 2022, the IPO closed, and the Company received approximately $13.8 million in net proceeds from the IPO after deducting the underwriting discount and commission and other estimated IPO expenses payable by the Company. As a result of the completion of the IPO, the Company converted the entirety of the outstanding principal and accrued interest of the convertible notes payable to 3,955,415 shares of the Company’s common stock. On April 29, 2022, as result of the completion of the IPO, the Company converted all shares of Series A and Series B Preferred Stock to 2,693,342 shares of the Company’s common stock at the conversion rate detailed below and issued the common stock to the preferred stockholders. Concurrent with the completion of the IPO and in accordance with the Amended and Restated Exclusive Sales Representative Agreement executed in May 2021, the counterparty to the agreement received anti-dilution protections to maintain ownership of 3.0% of the fully diluted equity of the Company through the date of an initial public offering and was issued 312,351 shares of the Company’s common stock to the Representative, fully satisfying the Company’s obligations. Also, as a result of the completion of the IPO, the Company issued 85,739 shares of its common stock to a consultant. The value of these shares issued at the IPO price of $5.00 per share was charged to operating expenses in the Company’s consolidated Voting rights The holders of vested shares of common stock are entitled to vote on any matter submitted to a vote of the stockholders and each such holder is entitled to one vote per share of common stock held. The holders of Series A and Series B Preferred Stock were entitled to vote together with the common stock as a single class on any matter submitted to a vote of the stockholders. Holders of Series A and Series B Preferred Stock were entitled to the number of votes equal to the number of common stock issuable upon conversion of their respective Series A and Series B Preferred Stock at the time such shares are voted. The holders of a majority of the preferred stock had additional voting rights as specified in the Company’s Amended and Restated Certificate of Incorporation, as amended. Equity awards In 2012, the Board of Directors of the Company (the “Board”) approved the Tenon Medical, Inc. 2012 Equity Incentive Plan (the “2012 Plan”). The 2012 Plan provides for the issuance of common stock options, appreciation rights, and other awards to employees, directors, and consultants. Options issued under the 2012 Plan generally vest over a period of two On January 10, 2022 and February 2, 2022, the Board and stockholders, respectively, of the Company approved the Tenon Medical, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), which was effective on April 25, 2022. The number of shares of common stock that may be subject to awards and sold under the 2022 Plan is equal to 1,600,000. Automatic annual increases in number of shares available for issuance under the 2022 Plan is equal to the least of (a) 1,100,000 shares, (b) 4% of the total number of shares of all classes of common stock outstanding on the last day of the immediately preceding fiscal year, or (c) such number determined by the 2022 Plan administrator no later than the last day of the immediately preceding fiscal year. Annual increases will continue until the tenth anniversary of the earlier of the Board or stockholder approval of the 2022 Plan, which is January 10, 2032. Upon the effective date of the 2022 Plan, the Board terminated the 2012 Plan such that no new equity awards will be issued by the 2012 Plan. Compensation expense for the three months ended March 31, 2023 and 2022 includes the portion of awards vested in the periods for all equity-based awards granted, based on the grant date fair value estimated using a Black-Scholes option valuation model. A summary of the Company’s stock Number of Shares Subject to Outstanding Stock Options Weighted Average Exercise Price p Share Number of Outstanding Restricted Stock Units Weighted A Date Fair Value per Share Outstanding at December 31, 2022 898,844 $ 4.74 1,318,530 $ 7.93 Granted 75,500 $ 2.32 — — Released — — (14,498 ) $ 2.75 Forfeited — — — — Outstanding at March 31, 2023 974,344 $ 4.55 1,304,032 $ 7.99 The following table sets forth stock-based compensation expense recognized for the three months ended March 31, 2023 and 2022: Three months ended March 31, 2023 2022 Research and development $ 372 $ 29 Sales and marketing 58 12 General, and administrative 610 128 Total stock-based compensation expense $ 1,040 $ 169 At March 31, 2023, there were 483,992 Warrants In April 2022, as noted above, the Company granted the Underwriters warrants to purchase a total of 96,000 shares of the Company’s common stock. The warrants are immediately exercisable at an exercise price of $5.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO. The fair value of the warrants on the grant date was $2.75 per warrant, which was calculated based on the following weighted

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Sales Representative Agreement In April 2020, the Company entered into an Exclusive Sales Representative Agreement, under which the counterparty to the agreement (the “Representative”) received exclusive rights to market, promote, and distribute The Catamaran , of common stock of common stock The Restated Sales Agreement Restated Sales Agreement On October 6, 2022, the Company entered into the Terminating Amended and Restated Exclusive Sales Representative Agreement (the “Termination Agreement”) with the Representative, which terminated the Restated Sales Agreement. In accordance with the Termination Agreement, (i) the Company paid the Representative $1,000 in cash; and (ii) the Company agreed to pay the Representative (a) $85 per month during the six months after the date of the Termination Agreement in return for efforts by the Representative to transition operations to the Company, (b) 20% of net sales of the p with a 25% quarterly estimated standard deviation of growth rates and a 10% probability of dissolution, discounted at an estimated discount rate of 15.4%. Based on the Company’s fair value analysis, a total of $2,611 was charged to sales and marketing expense in the consolidated statements of operations and comprehensive loss and recorded as accrued commissions in the consolidated balance sheets is as follows: 2023 Balance at December 3 $ 2,560 Amounts paid during 2023 (77 ) Accretion 204 Balance at March 31, 2023 $ 2,687 Per the terms of the Termination Agreement, the Company ultimately expects to expense $3,600 under clause (b) and clause (c). Simultaneously with the execution of the Termination Agreement, the Company entered into a Consulting Agreement dated October 6, 2022, with the Representative (the “Consulting Agreement”). Under the terms and conditions of the Consulting Agreement, the Representative is tasked with organizing, recruiting, training, and coordinating the Company’s Clinical Specialist program, Physician Education program and Sales Education program as more specifically described in the Consulting Agreement. The term of the Consulting Agreement is from October 6, 2022, until October 05, 2023, unless extended by mutual agreement of the parties in writing for additional one-year terms, or terminated in accordance with the terms of the Consulting Agreement. In consideration for the services to be provided, the Company shall pay the Representative a base consulting fee of $700 per year, payable in monthly instal l Litigation In the normal course of business, the Company may possibly be named as a defendant in various lawsuits.

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Concentrations of Risk	9. Concentrations of Risk Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances at financial institutions located in California and Switzerland. Accounts at the U.S. financial institutions are secured by the Federal Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. The Company grants unsecured credit to its customers based on an evaluation of the customer’s financial condition and a cash deposit is generally not required. Management believes its credit policies do not result in significant adverse risk and historically has not experienced significant credit-related losses. Currency risk The Company’s subsidiary, Tenon Technology AG, realizes a portion of its expenses in Swiss francs. Consequently, certain assets and liabilities are exposed to foreign currency fluctuations. At March 31, 2023 and December 31, 2022, approximately $22 and $8, respectively, of the Company’s net monetary assets were denominated in Swiss francs. The Company has not entered into any hedging transactions to reduce the exposure to currency risk.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). As permitted under these rules and regulations, the Company has condensed or omitted certain financial information and footnote disclosures normally included in its annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2022 has been derived from the Company’s audited consolidated financial statements, which are included in its Annual Report on Form 10-K filed with the SEC on March 10, 2023. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in management’s opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of its financial information. The interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These unaudited condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021 included in its Annual Report of Form 10-K filed with the SEC on March 10, 2023. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements as of and for the years ended December 31, 2022 and 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2023.
Going concern uncertainty and liquidity requirements	Going concern uncertainty and liquidity requirements The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these financial statements are issued. Since inception, the Company has incurred losses and negative cash flows from operations. Management expects to incur additional operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs and the commercialization of The Catamaran System. On April 29, 2022, the Company closed an initial public offering (the “IPO”) of its common stock for proceeds of $13,765, net of issuance costs. Based on the Company’s current level of revenues and expenditures, the Company believes that its existing cash and cash equivalents and short-term investments as of March 31, 2023 will not provide sufficient funds to enable it to meet its obligations for a period of at least twelve months from the date of the filing of these condensed consolidated financial statements. The Company plans to raise the necessary additional capital through one or a combination of public or private equity offerings, debt financings, and collaborations. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, realization of deferred tax assets, accrued liabilities, accrued commissions, incremental borrowing rate, obsolescence
Income Taxes	Income Taxes The Company accounts for income taxes utilizing ASC 740, “Income Taxes”. ASC 740 requires the measurement of deferred tax assets for deductible temporary differences and operating loss carry forwards, and of deferred tax liabilities for taxable temporary differences. Measurement of current and deferred tax liabilities and assets is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not included in the measurement. The Company recognizes the amount of taxes payable or refundable for the current year and recognizes deferred tax liabilities and assets for the expected future tax consequences of events and transactions that have been recognized in the Company’s financial statements or tax returns. The Company currently has substantial net operating loss carry forwards. The Company has recorded a 100% valuation allowance against net deferred tax assets due to uncertainty of their ultimate realization. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
Net loss per share	Net loss per share Basic net loss per share is based upon the weighted The Company had the following dilutive common stock equivalents as of March 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive: March 31, March 31, Outstanding restricted stock units 1,304,032 — Outstanding stock options 974,344 727,394 Outstanding warrants 96,000 25,000 Common shares convertible from notes payable — 2,118,591 Common shares convertible from preferred stock — 1,520,996 Total 2,374,376 4,391,981
Recent Accounting Pronouncements Adopted	Recent Accounting Pronouncements Adopted In June 2016, the Financial Accounting Standards Board issued Accounting Standards Update 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). This standard requires an impairment model (known as the current expected credit loss (“CECL”) model) that is based on expected losses rather than incurred losses. Under the new guidance, each reporting entity estimate s on of Recent Accounting Pronouncements Not Yet Adopted There have been no accounting pronouncements or changes in accounting pronouncements in the three months ended March 31, 2023 that are significant or

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Securities Excluded Due To Anti Dilutive Effect	The Company had the following dilutive common stock equivalents as of March 31, 2023 and 2022 which were excluded from the calculation because their effect was anti-dilutive: March 31, March 31, Outstanding restricted stock units 1,304,032 — Outstanding stock options 974,344 727,394 Outstanding warrants 96,000 25,000 Common shares convertible from notes payable — 2,118,591 Common shares convertible from preferred stock — 1,520,996 Total 2,374,376 4,391,981

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Investments [Abstract]
Schedule of Investments At Fair Value in Fair Value Hierarchy Level	The following table sets forth by level, within the fair value hierarchy, the Company’s investments at fair value as of March 31, 2023 and December 31, 2022: Level 2 Corporate debt securities: March 31, 2023 $ 1,737 December 31, 2022 $ 6,441
Schedule of Cost And Fair Value of Available For Sale Investments	Cost and fair value of available-for-sale investments as of March 31, 2023 and December 31, 2022 are as follows: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate debt securities: March 31, 2023 $ 1,740 $ — $ (3 ) $ 1,737 December 31, 2022 $ 6,457 $ — $ (16 ) $ 6,441

Fixed Assets, Net (Tables)

Fixed Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Fixed Assets	Fixed assets, net, consisted of the following: March 31, 2023 December 31, 2022 Construction in progress $ 530 $ 601 Catamaran t s 348 193 IT e 556 56 Lab e 14 14 Office f 9 9 Fixed assets, gross 957 873 Less: accumulated depreciation (105 ) (80 ) Fixed assets, net $ 852 $ 793

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following: March 31, 2023 December 31, 2022 Accrued compensation $ 321 $ 452 Other accrued expenses 209 265 Total accrued expenses $ 530 $ 717

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Summary of Supplemental Balance Sheet Information Related To Leases	Supplemental balance sheet information related to leases was as follows: March 31, December 31, 2023 2022 Operating lease right-of-use assets $ 818 $ 873 Operating lease liability, current $ (235 ) $ (228 ) Operating lease liability, noncurrent (622 ) (683 ) Total operating lease liabilities $ (857 ) $ (911 )
Summary of Future Maturities of Operating Lease Liabilities	Future maturities of operating lease liabilities as of March 31, 2023 were as follows: 2023 $ 221 2024 301 2025 310 2026 144 Total lease payments 976 Less: imputed interest (119 ) Present value of operating lease liabilities $ 857 Other information: Cash paid for operating leases for the three months ended March 31, 2023 $ 72 Cash paid for operating leases for the three months ended March 31, 2022 $ 70 Remaining lease term - operating leases (in years) 3.25 Average discount rate - operating leases 8.0 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Summary of Share Based Compensation Arrangements By Share Based Payment Award	A summary of the Company’s stock Number of Shares Subject to Outstanding Stock Options Weighted Average Exercise Price p Share Number of Outstanding Restricted Stock Units Weighted A Date Fair Value per Share Outstanding at December 31, 2022 898,844 $ 4.74 1,318,530 $ 7.93 Granted 75,500 $ 2.32 — — Released — — (14,498 ) $ 2.75 Forfeited — — — — Outstanding at March 31, 2023 974,344 $ 4.55 1,304,032 $ 7.99
Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs	The following table sets forth stock-based compensation expense recognized for the three months ended March 31, 2023 and 2022: Three months ended March 31, 2023 2022 Research and development $ 372 $ 29 Sales and marketing 58 12 General, and administrative 610 128 Total stock-based compensation expense $ 1,040 $ 169

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Summary of reconciliation of the liability under clause (b) and clause (c)	2023 Balance at December 3 $ 2,560 Amounts paid during 2023 (77 ) Accretion 204 Balance at March 31, 2023 $ 2,687

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Schedule of Securities Excluded Due To Anti Dilutive Effect (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,374,376	4,391,981
Outstanding restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,304,032	0
Outstanding stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	974,344	727,394
Outstanding warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	96,000	25,000
Common shares convertible from notes payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,118,591
Common shares convertible from preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,520,996

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Apr. 29, 2022	Mar. 31, 2023
Accounting Policies [Abstract]
Percentage of valuation allowance in deferred tax assets		100%
Proceeds from Issuance of Common Stock	$ 13,765

Investments - Schedule of Inves

Investments - Schedule of Investments At Fair Value in Fair Value Hierarchy Level (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	$ 1,737	$ 6,441

Investments - Schedule of Cost

Investments - Schedule of Cost And Fair Value of Available For Sale Investments (Detail) - Corporate Debt Securities [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 1,740	$ 6,457
Unrealized ‎Gains	0	0
Unrealized Losses	(3)	(16)
Fair Value	$ 1,737	$ 6,441

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Other than temporary impairment losses	$ 0	$ 0
Net gain on investments	56	$ 1
Prepaid Expenses and Other Current Assets [Member]
Accrued interest	$ 10		$ 13

Fixed Assets, Net - Summary of

Fixed Assets, Net - Summary of Fixed Assets and Equipment Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fixed Assets [Line Items]
Fixed Assets, gross	$ 957	$ 873
Less: accumulated depreciation	(105)	(80)
Fixed Assets, net	852	793
Construction in progress [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	530	601
Catamaran tray sets [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	348	193
IT equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	556	56
Lab equipment [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	14	14
Office furniture [Member]
Fixed Assets [Line Items]
Fixed Assets, gross	$ 9	$ 9

Fixed Assets, Net - Additional

Fixed Assets, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 25	$ 10

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued compensation	$ 321	$ 452
Other accrued expenses	209	265
Total accrued expenses	$ 530	$ 717

Leases - Summary of Supplementa

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Lessee Disclosure [Abstract]
Operating lease right-of-use assets	$ 818	$ 873
Operating lease liability, current	(235)	(228)
Operating lease liability, noncurrent	(622)	(683)
Total operating lease liabilities	$ (857)	$ (911)

Leases - Summary of Future Matu

Leases - Summary of Future Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Lessee Disclosure [Abstract]
2023	$ 221
2024	301
2025	310
2026	144
Total lease payments	976
Less: imputed interest	(119)
Present value of operating lease liabilities	857		$ 911
Cash paid for operating leases	$ 72	$ 70
Remaining lease term - operating leases (in years)	3 years 3 months
Average discount rate - operating leases	8%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Lessee, Operating lease, Expiration, Month and Year	2026-06
General and Administrative Expense [Member]
Operating lease costs		$ 73	$ 135

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

Apr. 29, 2022 USD ($) $ / shares shares

Apr. 06, 2022

Apr. 30, 2022 USD ($) yr $ / shares shares

Oct. 31, 2021 shares

May 31, 2021 shares

Mar. 31, 2023 $ / shares shares

Dec. 31, 2022 $ / shares shares

Apr. 26, 2022 $ / shares shares

Apr. 25, 2022 shares

Feb. 28, 2022 shares

Aug. 31, 2021 shares

Jul. 31, 2021 shares

Apr. 30, 2021 shares

Feb. 18, 2014 $ / shares shares

Common stock, Shares authorized

10,487,904

130,000,000

130,000,000

130,000,000

7,000,000

3,937,550

Common stock, Par or stated value per share | $ / shares

$ 0.001

$ 0.001

$ 0.001

Common stock, Voting rights

one vote

Stock issued during period, shares, issued for services to consultant

85,739

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $

$ 0

Stockholders' equity, reverse stock split

1:2 reverse stock split

Common Stock, Conversion Basis

one-to-0.5

Representative [Member] | Other [Member]

Ownership Percentage

3%

IPO [Member]

Common stock, Par or stated value per share | $ / shares

$ 0.001

Common stock shares subscribed but unissued

3,200,000

Sale of stock, price per share | $ / shares

$ 5

$ 5

Net proceeds from the IPO after deducting expenses | $

$ 13,800

Common Stock Warrants [Member] | Consultant [Member]

Class of warrant or right, number of common stock called by warrants or rights

96,000

Class of warrants or rights exercise price | $ / shares

$ 5

Class of warrants of rights grant date fair value of warrants | $ / shares

$ 2.75

Deferred costs associated with warrants | $

$ 264

Common Stock Warrants [Member] | Consultant [Member] | Measurement Input, Expected Term [Member]

Warrants and Rights Outstanding, Measurement Input | yr

5

Common Stock Warrants [Member] | Consultant [Member] | Measurement Input, Price Volatility [Member]

Warrants and Rights Outstanding, Measurement Input

62.55

Common Stock Warrants [Member] | Consultant [Member] | Measurement Input, Expected Dividend Rate [Member]

Warrants and Rights Outstanding, Measurement Input

0

Common Stock Warrants [Member] | Consultant [Member] | Measurement Input, Risk Free Interest Rate [Member]

Warrants and Rights Outstanding, Measurement Input

2.92

Conversion of Convertible Notes to Common Stock [Member]

Number of shares issued during the period on conversion of convertible notes

3,955,415

Conversion of Series A and Series B Preferred Stock to Common Stock [Member]

Conversion of stock, Shares issued

2,693,342

Two Thousand And Twelve Plan [Member]

Common Stock, Capital Shares Reserved for Future Issuance

737,516

662,516

Two Thousand and Twenty Two Equity Incentive Plan [Member]

Stock issued during period, Shares, New issues

483,992

Share based compensation by share based payment award number of shares available for grant

1,600,000

Share based compensation arrangement by share based payment award cumulative annual increase shares

1,100,000

Share based compensation arrangement by share based payment award cumulative annual increase percentage

4%

Employee Stock Option [Member] | Two Thousand And Twelve Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Minimum [Member] | Two Thousand And Twelve Plan [Member]

Common Stock, Capital Shares Reserved for Future Issuance

737,516

Minimum [Member] | Employee Stock Option [Member] | Two Thousand And Twelve Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

2 years

Maximum [Member] | Two Thousand And Twelve Plan [Member]

Common Stock, Capital Shares Reserved for Future Issuance

799,266

Maximum [Member] | Employee Stock Option [Member] | Two Thousand And Twelve Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

4 years

Underwriting Agreement [Member]

Class of warrant or right, number of common stock called by warrants or rights

96,000

Class of warrants or rights exercise price | $ / shares

$ 5

Amended and Restated Exclusive Sales Representative Agreement [Member] | Representative [Member]

Stock issued during period, Shares, New issues

312,351

44,447

53,757

Amended and Restated Exclusive Sales Representative Agreement [Member] | Representative [Member] | Other [Member]

Ownership Percentage

3%

Convertible Preferred Stock [Member]

Temporary equity, Shares authorized

3,297,061

20,000,000

2,460,802

2,099,525

Series A Convertible Preferred Stock [Member]

Temporary equity, Shares authorized

4,500,000

1,798,905

Series B Convertible Preferred Stock [Member]

Temporary equity, Shares authorized

491,222

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Share Based Compensation Arrangements By Share Based Payment Award (Detail)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Number of Outstanding Restricted Stock Units (Beginning Balance) | shares	1,318,530
Number of Outstanding Restricted Stock Units Granted | shares	0
Number of Outstanding Restricted Stock Units Released | shares	(14,498)
Number of Outstanding Restricted Stock Units Forfeited | shares	0
Number of Outstanding Restricted Stock Units (Ending Balance) | shares	1,304,032
Weighted-average Grant Date Fair Value per Share (Beginning Balance) | $ / shares	$ 7.93
Weighted-average Grant Date Fair Value per Share Granted | $ / shares	0
Weighted-average Grant Date Fair Value per Share Released | $ / shares	2.75
Weighted-average Grant Date Fair Value per Share Forfeited | $ / shares	0
Weighted-average Grant Date Fair Value per Share (Ending Balance) | $ / shares	$ 7.99
Share-based Payment Arrangement, Option [Member]
Number of Shares Subject to Outstanding Stock Options (Beginning Balance) | shares	898,844
Number of Shares Subject to Outstanding Stock Options Granted | shares	75,500
Number of Shares Subject to Outstanding Stock Options Forfeited | shares	0
Number of Shares Subject to Outstanding Stock Options Outstanding (Ending Balance) | shares	974,344
Weighted Average Exercise Price Per Share Outstanding (Beginning Balance) | $ / shares	$ 4.74
Weighted Average Exercise Price Per Share Granted | $ / shares	2.32
Weighted Average Exercise Price Per Share Forfeited | $ / shares	0
Weighted Average Exercise Price Per Share Outstanding (Ending Balance) | $ / shares	$ 4.55

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Employee Service Share Based Compensation Allocation of Recognized Period Costs (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 1,040	$ 169
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	372	29
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	58	12
General, and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Payment Arrangement, Expense	$ 610	$ 128

Commitments and Contingencies -

Commitments and Contingencies - Summary Of Reconciliation Of The Liability Under Clause (B) And Clause (C) (Details) - Representative [Member] - Termination Agreement [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Disclosure Of Reconciliation Of Liability [Line Items]
Balance at January 1, 2022	$ 2,560
Amounts paid during 2023	(77)
Accretion	204
Balance at March 31, 2023	$ 2,687

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - USD ($)				1 Months Ended			3 Months Ended
	Dec. 31, 2023	Oct. 06, 2022	Apr. 29, 2022	Oct. 31, 2021	May 31, 2021	Apr. 30, 2020	Mar. 31, 2023	Mar. 31, 2022
Other Commitments [Line Items]
Sales and marketing expense							$ 2,026,000	$ 276,000
Representative [Member] | Other [Member]
Other Commitments [Line Items]
Ownership Percentage			3%
Sales Representative Agreement [Member]
Other Commitments [Line Items]
Agreement term						5 years
Agreement additional extension term						5 years
Amended and Restated Exclusive Sales Representative Agreement [Member] | Representative [Member]
Other Commitments [Line Items]
Payment of representative bonus					$ 500,000
Stock issued during period shares new issues			312,351	44,447	53,757
Sales and marketing expense					$ 880,000
Stock issued during period value new issues				$ 333,000
Minimum representative bonus payable				$ 6,000,000
Amended and Restated Exclusive Sales Representative Agreement [Member] | Representative [Member] | Other [Member]
Other Commitments [Line Items]
Ownership Percentage					3%
Termination Agreement [Member] | Representative [Member]
Other Commitments [Line Items]
Payment to representative as per agreement		$ 1,000,000					1,000,000
As per agreement value agreed to pay the representative per month		$ 85,000					$ 85,000
Percentage of net sales of the product sold agreed to pay the representative		20%
Percentage of commission to net sales agreed to pay the representative until aggregate amount paid		10%
Value of commission agreed to pay as per agreement		$ 3,600,000
As per agreement value to pay the representative in the event of acquisition net of previous amount paid		$ 3,600,000
Fair value discount rate							15.40%
Fair value analysis charge							$ 2,611,000
Ultimately expects to expense amount	$ 3,600,000
Termination Agreement [Member] | Representative [Member] | Fair Value, Inputs, Level 3 [Member]
Other Commitments [Line Items]
Growth rates of fair value of liability							25%
Dissolution rate of fair value of liability							10%
Consulting Agreement [Member]
Other Commitments [Line Items]
Term of agreement		October 6, 2022, until October 05, 2023
Additional term of agreement by mutual agreement of the parties in writing		1 year
Consulting Agreement [Member] | Representative [Member]
Other Commitments [Line Items]
Consulting fee per year payable in monthly installments		$ 700,000
Additional compensation payable per quarter		$ 62,500

Concentrations of Risk - Additi

Concentrations of Risk - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Switzerland, Francs [Member] | Net Assets, Geographic Area [Member]
Concentration Risk [Line Items]
Net assets	$ 22	$ 8